CHEBI ONTOLOGY - ANNOTATIONS
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/ . The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/ ). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term: testosterone undecanoate
Accession: CHEBI:135741
browse the term
Synonyms: related_synonym: Formula=C30H48O3; InChI=1S/C30H48O3/c1-4-5-6-7-8-9-10-11-12-28(32)33-27-16-15-25-24-14-13-22-21-23(31)17-19-29(22,2)26(24)18-20-30(25,27)3/h21,24-27H,4-20H2,1-3H3/t24-,25-,26-,27-,29-,30-/m0/s1; InChIKey=UDSFVOAUHKGBEK-CNQKSJKFSA-N; SMILES=C[C@@]12[C@@]3([C@]([C@]4([C@@](CC3)(C)[C@H](CC4)OC(CCCCCCCCCC)=O)[H])(CCC1=CC(CC2)=O)[H])[H]; testosterone undecylate
xref: CAS:5949-44-0; Drug_Central:2608
xref_mesh: MESH:C010792
G
Abhd5
abhydrolase domain containing 5, lysophosphatidic acid acyltransferase
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ABHD5 mRNA
CTD
PMID:19074003
NCBI chr 8:130,973,222...131,001,448
Ensembl chr 8:130,973,201...131,001,458
G
Ace2
angiotensin I converting enzyme 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ACE2 mRNA
CTD
PMID:19074003
NCBI chr X:32,050,734...32,095,860
Ensembl chr X:32,049,931...32,096,016
G
Adgrf5
adhesion G protein-coupled receptor F5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of ADGRF5 mRNA
CTD
PMID:19074003
NCBI chr 9:20,091,121...20,195,706
Ensembl chr 9:20,091,099...20,195,566
G
Afg1l
AFG1 like ATPase
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of AFG1L mRNA
CTD
PMID:19074003
NCBI chr20:47,038,824...47,208,812
G
Ahctf1
AT hook containing transcription factor 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of AHCTF1 mRNA
CTD
PMID:19074003
NCBI chr13:98,023,528...98,079,138
Ensembl chr13:98,023,430...98,078,946
G
Alms1
ALMS1, centrosome and basal body associated protein
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ALMS1 mRNA
CTD
PMID:19074003
NCBI chr 4:117,371,544...117,472,310
Ensembl chr 4:117,371,659...117,472,198
G
Alpk2
alpha-kinase 2
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of ALPK2 mRNA testosterone undecanoate results in increased expression of ALPK2 mRNA
CTD
PMID:19074003
NCBI chr18:60,960,009...61,072,116
Ensembl chr18:60,960,662...61,057,365
G
Ammecr1
AMMECR nuclear protein 1
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of AMMECR1 mRNA testosterone undecanoate results in decreased expression of AMMECR1 mRNA
CTD
PMID:19074003
NCBI chr X:114,129,829...114,233,013
Ensembl chr X:114,131,898...114,232,939
G
Ampd3
adenosine monophosphate deaminase 3
increases expression
ISO
testosterone undecanoate results in increased expression of AMPD3 mRNA
CTD
PMID:19074003
NCBI chr 1:175,585,301...175,630,479
Ensembl chr 1:175,586,097...175,630,467
G
Ankdd1a
ankyrin repeat and death domain containing 1A
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ANKDD1A mRNA
CTD
PMID:19074003
NCBI chr 8:71,034,630...71,057,265
Ensembl chr 8:71,035,309...71,055,969
G
Api5
apoptosis inhibitor 5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of API5 mRNA
CTD
PMID:19074003
NCBI chr 3:83,310,878...83,336,053
Ensembl chr 3:83,310,884...83,335,960
G
Arhgap23
Rho GTPase activating protein 23
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of ARHGAP23 mRNA testosterone undecanoate results in increased expression of ARHGAP23 mRNA
CTD
PMID:19074003
NCBI chr10:85,387,219...85,445,805
Ensembl chr10:85,384,881...85,444,556
G
Arl9
ADP-ribosylation factor like GTPase 9
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of ARL9 mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of ARL9 mRNA
CTD
PMID:19074003
NCBI chr14:33,436,803...33,447,516
Ensembl chr14:33,436,980...33,444,235
G
Asap1
ArfGAP with SH3 domain, ankyrin repeat and PH domain 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ASAP1 mRNA
CTD
PMID:19074003
NCBI chr 7:104,670,076...104,951,090
Ensembl chr 7:104,669,672...104,801,045
G
Azgp1
alpha-2-glycoprotein 1, zinc-binding
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of AZGP1 mRNA testosterone undecanoate results in decreased expression of AZGP1 mRNA
CTD
PMID:19074003
NCBI chr12:19,196,565...19,203,094
Ensembl chr12:19,196,611...19,202,647
G
B4galt5
beta-1,4-galactosyltransferase 5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of B4GALT5 mRNA
CTD
PMID:19074003
NCBI chr 3:164,039,731...164,055,561
Ensembl chr 3:164,039,731...164,095,878
G
Bbx
BBX high mobility group box domain containing
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of BBX mRNA
CTD
PMID:19074003
NCBI chr11:52,983,286...53,228,557
Ensembl chr11:53,081,025...53,228,716
G
Bcl2l14
BCL2 like 14
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of BCL2L14 mRNA testosterone undecanoate results in increased expression of BCL2L14 mRNA
CTD
PMID:19074003
NCBI chr 4:168,139,964...168,183,726
Ensembl chr 4:168,142,271...168,183,096
G
Btbd3
BTB domain containing 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of BTBD3 mRNA
CTD
PMID:19074003
NCBI chr 3:131,330,338...131,360,554
Ensembl chr 3:131,351,587...131,357,929
G
Ccn3
cellular communication network factor 3
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CCN3 mRNA testosterone undecanoate results in decreased expression of CCN3 mRNA
CTD
PMID:19074003
NCBI chr 7:94,375,134...94,382,154
Ensembl chr 7:94,375,020...94,383,024
G
Cd86
CD86 molecule
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of CD86 mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CD86 mRNA
CTD
PMID:19074003
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
G
Cdc25c
cell division cycle 25C
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CDC25C mRNA
CTD
PMID:19074003
NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
G
Cdc42bpb
CDC42 binding protein kinase beta
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CDC42BPB mRNA
CTD
PMID:19074003
NCBI chr 6:135,746,743...135,830,144
Ensembl chr 6:135,746,754...135,830,086
G
Cdc42ep1
CDC42 effector protein 1
decreases expression
ISO
testosterone undecanoate results in decreased expression of CDC42EP1 mRNA
CTD
PMID:19074003
NCBI chr 7:120,063,256...120,071,154
Ensembl chr 7:120,067,379...120,071,440
G
Cep170b
centrosomal protein 170B
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CEP170B mRNA
CTD
PMID:19074003
NCBI chr 6:137,283,814...137,311,512
Ensembl chr 6:137,288,810...137,311,932
G
Cfap65
cilia and flagella associated protein 65
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CFAP65 mRNA
CTD
PMID:19074003
NCBI chr 9:82,163,016...82,197,909
Ensembl chr 9:82,163,075...82,195,722
G
Chek2
checkpoint kinase 2
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CHEK2 mRNA testosterone undecanoate results in decreased expression of CHEK2 mRNA
CTD
PMID:19074003
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
G
Chodl
chondrolectin
decreases expression
ISO
testosterone undecanoate results in decreased expression of CHODL mRNA
CTD
PMID:19074003
NCBI chr11:17,537,980...17,560,305
Ensembl chr11:17,538,063...17,560,296
G
Chp2
calcineurin-like EF hand protein 2
decreases expression
ISO
testosterone undecanoate results in decreased expression of CHP2 mRNA
CTD
PMID:19074003
NCBI chr 1:192,169,634...192,173,228
Ensembl chr 1:192,169,841...192,173,253
G
Cntf
ciliary neurotrophic factor
increases expression
ISO
testosterone undecanoate results in increased expression of CNTF mRNA
CTD
PMID:19074003
NCBI chr 1:229,599,009...229,601,032
Ensembl chr 1:229,599,009...229,601,032
G
Col1a1
collagen type I alpha 1 chain
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of COL1A1 mRNA
CTD
PMID:19074003
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
G
Col22a1
collagen type XXII alpha 1 chain
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of COL22A1 mRNA testosterone undecanoate results in increased expression of COL22A1 mRNA
CTD
PMID:19074003
NCBI chr 7:113,014,896...113,251,165
Ensembl chr 7:113,015,747...113,228,439
G
Corin
corin, serine peptidase
increases expression
ISO
testosterone undecanoate results in increased expression of CORIN mRNA
CTD
PMID:19074003
NCBI chr14:38,247,379...38,474,931
Ensembl chr14:38,247,791...38,473,648
G
Cpeb3
cytoplasmic polyadenylation element binding protein 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CPEB3 mRNA
CTD
PMID:19074003
NCBI chr 1:255,660,165...255,842,671
Ensembl chr 1:255,665,238...255,815,733
G
Cpxcr1
CPX chromosome region, candidate 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CPXCR1 mRNA
CTD
PMID:19074003
NCBI chr X:49,243,273...49,244,985
G
Crlf3
cytokine receptor-like factor 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CRLF3 mRNA
CTD
PMID:19074003
NCBI chr10:67,383,664...67,401,836
Ensembl chr10:67,383,900...67,401,836
G
Csmd1
CUB and Sushi multiple domains 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CSMD1 mRNA
CTD
PMID:19074003
NCBI chr16:77,152,823...78,850,222
Ensembl chr16:78,539,489...78,850,222
G
Csnk1a1
casein kinase 1, alpha 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CSNK1A1 mRNA
CTD
PMID:19074003
NCBI chr18:56,887,722...56,910,610
Ensembl chr18:56,887,354...56,918,345
G
Cxcl10
C-X-C motif chemokine ligand 10
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of CXCL10 mRNA testosterone undecanoate results in increased expression of CXCL10 mRNA
CTD
PMID:19074003
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
G
Cyp17a1
cytochrome P450, family 17, subfamily a, polypeptide 1
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of CYP17A1 mRNA testosterone undecanoate results in decreased expression of CYP17A1 mRNA
CTD
PMID:19074003
NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
G
Dap3
death associated protein 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of DAP3 mRNA
CTD
PMID:19074003
NCBI chr 2:188,225,607...188,255,324
Ensembl chr 2:188,225,613...188,252,725
G
Dcn
decorin
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of DCN mRNA
CTD
PMID:19074003
NCBI chr 7:38,742,250...38,782,282
Ensembl chr 7:38,742,051...38,782,323
G
Ddhd1
DDHD domain containing 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of DDHD1 mRNA
CTD
PMID:19074003
NCBI chr15:19,963,639...20,032,263
Ensembl chr15:19,965,187...20,032,191
G
Dlgap2
DLG associated protein 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of DLGAP2 mRNA
CTD
PMID:19074003
NCBI chr16:79,872,238...80,596,977
Ensembl chr16:79,872,323...79,973,877
G
Dnase1l3
deoxyribonuclease 1-like 3
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of DNASE1L3 mRNA testosterone undecanoate results in decreased expression of DNASE1L3 mRNA
CTD
PMID:19074003
NCBI chr15:18,710,492...18,736,476
Ensembl chr15:18,710,492...18,736,473
G
Dock8
dedicator of cytokinesis 8
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of DOCK8 mRNA
CTD
PMID:19074003
NCBI chr 1:242,934,685...243,153,472
Ensembl chr 1:242,959,488...243,153,465
G
Dok5
docking protein 5
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of DOK5 mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of DOK5 mRNA
CTD
PMID:19074003
NCBI chr 3:168,345,116...168,482,445
Ensembl chr 3:168,345,152...168,482,441
G
Dsg1
desmoglein 1
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of DSG1 mRNA testosterone undecanoate results in increased expression of DSG1 mRNA
CTD
PMID:19074003
NCBI chr18:12,008,301...12,040,337
Ensembl chr18:12,008,759...12,038,053
G
Elovl5
ELOVL fatty acid elongase 5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ELOVL5 mRNA
CTD
PMID:19074003
NCBI chr 8:85,220,941...85,287,449
Ensembl chr 8:85,259,982...85,285,983
G
Eprs
glutamyl-prolyl-tRNA synthetase
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of EPRS1 mRNA
CTD
PMID:19074003
NCBI chr13:103,300,911...103,371,651
Ensembl chr13:103,300,932...103,371,577
G
Etnk1
ethanolamine kinase 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ETNK1 mRNA
CTD
PMID:19074003
NCBI chr 4:177,402,904...177,447,047
Ensembl chr 4:177,402,904...177,447,028
G
Evi2b
ecotropic viral integration site 2B
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of EVI2B mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of EVI2B mRNA
CTD
PMID:19074003
NCBI chr10:66,856,980...66,858,598
Ensembl chr10:66,856,980...66,858,598
G
Fam20a
FAM20A, golgi associated secretory pathway pseudokinase
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of FAM20A mRNA
CTD
PMID:19074003
NCBI chr10:97,962,467...98,017,171
Ensembl chr10:97,962,693...98,018,014
G
Far2
fatty acyl CoA reductase 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of FAR2 mRNA
CTD
PMID:19074003
NCBI chr 4:182,446,400...182,563,485
Ensembl chr 4:182,483,194...182,565,436
G
Fbxl20
F-box and leucine-rich repeat protein 20
decreases expression
ISO
testosterone undecanoate results in decreased expression of FBXL20 mRNA
CTD
PMID:19074003
NCBI chr10:86,036,745...86,099,699
Ensembl chr10:86,043,235...86,098,694
G
Fcrl5
Fc receptor-like 5
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of FCRL5 mRNA testosterone undecanoate results in increased expression of FCRL5 mRNA
CTD
PMID:19074003
NCBI chr 2:186,776,466...186,797,900
Ensembl chr 2:186,776,605...186,808,078
G
Fermt2
fermitin family member 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of FERMT2 mRNA
CTD
PMID:19074003
NCBI chr15:19,807,806...19,876,557
Ensembl chr15:19,807,808...19,876,408
G
Fkbp6
FKBP prolyl isomerase family member 6
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of FKBP6 mRNA testosterone undecanoate results in increased expression of FKBP6 mRNA
CTD
PMID:19074003
NCBI chr12:24,365,941...24,438,088
Ensembl chr12:24,367,199...24,438,019
G
Fmnl3
formin-like 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of FMNL3 mRNA
CTD
PMID:19074003
NCBI chr 7:140,981,801...141,033,318
Ensembl chr 7:140,983,342...141,001,993
G
Fnbp1
formin binding protein 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of FNBP1 mRNA
CTD
PMID:19074003
NCBI chr 3:9,865,657...9,936,333
Ensembl chr 3:9,861,237...9,936,405
G
Fut1
fucosyltransferase 1
decreases expression
ISO
testosterone undecanoate results in decreased expression of FUT1 mRNA
CTD
PMID:19074003
NCBI chr 1:101,599,018...101,602,440
Ensembl chr 1:101,599,018...101,602,436
G
Gdf10
growth differentiation factor 10
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of GDF10 mRNA testosterone undecanoate results in decreased expression of GDF10 mRNA
CTD
PMID:19074003
NCBI chr16:10,250,508...10,262,383
Ensembl chr16:10,250,404...10,263,150
G
Gdpd3
glycerophosphodiester phosphodiesterase domain containing 3
increases expression
ISO
testosterone undecanoate results in increased expression of GDPD3 mRNA
CTD
PMID:19074003
NCBI chr 1:198,199,032...198,209,178
Ensembl chr 1:198,199,622...198,209,150
G
Glyr1
glyoxylate reductase 1 homolog
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of GLYR1 mRNA
CTD
PMID:19074003
NCBI chr10:10,725,830...10,759,471
Ensembl chr10:10,725,819...10,761,279
G
Gpr135
G protein-coupled receptor 135
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of GPR135 mRNA
CTD
PMID:19074003
NCBI chr 6:94,816,976...94,818,349
Ensembl chr 6:94,816,976...94,818,349
G
Greb1
growth regulating estrogen receptor binding 1
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of GREB1 mRNA testosterone undecanoate results in decreased expression of GREB1 mRNA
CTD
PMID:19074003
NCBI chr 6:41,932,941...42,002,770
Ensembl chr 6:41,932,244...42,002,819
G
Gzmk
granzyme K
increases expression
ISO
testosterone undecanoate results in increased expression of GZMK mRNA
CTD
PMID:19074003
NCBI chr 2:45,069,136...45,077,154
Ensembl chr 2:45,068,967...45,077,219
G
Herc4
HECT and RLD domain containing E3 ubiquitin protein ligase 4
decreases expression
ISO
testosterone undecanoate results in decreased expression of HERC4 mRNA
CTD
PMID:19074003
NCBI chr20:26,755,948...26,831,267
Ensembl chr20:26,755,911...26,830,931
G
Hmmr
hyaluronan-mediated motility receptor
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of HMMR mRNA testosterone undecanoate results in increased expression of HMMR mRNA
CTD
PMID:19074003
NCBI chr10:25,861,490...25,890,639
Ensembl chr10:25,861,490...25,890,639
G
Hnrnpa3
heterogeneous nuclear ribonucleoprotein A3
decreases expression
ISO
testosterone undecanoate results in decreased expression of HNRNPA3 mRNA
CTD
PMID:19074003
NCBI chr 3:62,481,222...62,491,356
Ensembl chr 3:62,481,323...62,487,227
G
Hoxc6
homeo box C6
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of HOXC6 mRNA testosterone undecanoate results in increased expression of HOXC6 mRNA
CTD
PMID:19074003
NCBI chr 7:144,612,230...144,626,036
Ensembl chr 7:144,623,555...144,625,516
G
Hpcal4
hippocalcin-like 4
decreases expression
ISO
testosterone undecanoate results in decreased expression of HPCAL4 mRNA
CTD
PMID:19074003
NCBI chr 5:140,870,127...140,882,242
Ensembl chr 5:140,870,140...140,882,244
G
Hpgd
15-hydroxyprostaglandin dehydrogenase
increases expression
ISO
testosterone undecanoate results in increased expression of HPGD mRNA
CTD
PMID:19074003
NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
G
Hspb9
heat shock protein family B (small) member 9
increases expression
ISO
testosterone undecanoate results in increased expression of HSPB9 mRNA
CTD
PMID:19074003
NCBI chr10:88,620,655...88,621,300
Ensembl chr10:88,620,655...88,621,300
G
Htr7
5-hydroxytryptamine receptor 7
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of HTR7 mRNA
CTD
PMID:19074003
NCBI chr 1:254,547,964...254,671,811
Ensembl chr 1:254,547,620...254,671,778
G
Ice2
interactor of little elongation complex ELL subunit 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ICE2 mRNA
CTD
PMID:19074003
NCBI chr 8:75,625,147...75,666,959
Ensembl chr 8:75,625,174...75,666,866
G
Ifi30
IFI30, lysosomal thiol reductase
increases expression
ISO
testosterone undecanoate results in increased expression of IFI30 mRNA
CTD
PMID:19074003
NCBI chr16:20,426,566...20,430,772
Ensembl chr16:20,426,566...20,430,752
G
Igfbp3
insulin-like growth factor binding protein 3
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of IGFBP3 mRNA testosterone undecanoate results in increased expression of IGFBP3 mRNA
CTD
PMID:19074003
NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
G
Igsf1
immunoglobulin superfamily, member 1
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of IGSF1 mRNA testosterone undecanoate results in decreased expression of IGSF1 mRNA
CTD
PMID:19074003
NCBI chr X:136,792,637...136,808,107
Ensembl chr X:136,792,643...136,807,885
G
Igsf6
immunoglobulin superfamily, member 6
increases expression
ISO
testosterone undecanoate results in increased expression of IGSF6 mRNA
CTD
PMID:19074003
NCBI chr 1:190,997,029...191,007,503
Ensembl chr 1:190,997,029...191,007,503
G
Inha
inhibin subunit alpha
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of INHA mRNA testosterone undecanoate results in decreased expression of INHA mRNA
CTD
PMID:19074003
NCBI chr 9:82,700,482...82,703,383
Ensembl chr 9:82,700,468...82,703,400
G
Insl3
insulin-like 3
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of INSL3 mRNA testosterone undecanoate results in decreased expression of INSL3 mRNA
CTD
PMID:19074003
NCBI chr16:20,120,753...20,122,702
Ensembl chr16:20,121,352...20,122,696
G
Insl6
insulin-like 6
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of INSL6 mRNA
CTD
PMID:19074003
NCBI chr 1:247,473,292...247,476,827
Ensembl chr 1:247,473,292...247,476,827
G
Itih4
inter-alpha-trypsin inhibitor heavy chain 4
increases expression
ISO
testosterone undecanoate results in increased expression of ITIH4 mRNA
CTD
PMID:19074003
NCBI chr16:6,970,367...6,985,538
Ensembl chr16:6,970,342...6,985,579
G
Katnal1
katanin catalytic subunit A1 like 1
increases expression
ISO
testosterone undecanoate results in increased expression of KATNAL1 mRNA
CTD
PMID:19074003
NCBI chr12:7,495,436...7,550,205
Ensembl chr12:7,208,850...7,271,872 Ensembl chr12:7,208,850...7,271,872
G
Kbtbd7
kelch repeat and BTB domain containing 7
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of KBTBD7 mRNA
CTD
PMID:19074003
NCBI chr15:61,692,041...61,696,506
G
Kcnh7
potassium voltage-gated channel subfamily H member 7
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of KCNH7 mRNA
CTD
PMID:19074003
NCBI chr 3:48,662,450...49,168,716
Ensembl chr 3:48,671,079...48,831,467
G
Kdsr
3-ketodihydrosphingosine reductase
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of KDSR mRNA
CTD
PMID:19074003
NCBI chr13:26,779,386...26,812,271
Ensembl chr13:26,780,633...26,812,215
G
Klhl11
kelch-like family member 11
increases expression
ISO
testosterone undecanoate results in increased expression of KLHL11 mRNA
CTD
PMID:19074003
NCBI chr10:88,378,695...88,389,252
Ensembl chr10:88,378,751...88,389,347
G
Klhl28
kelch-like family member 28
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of KLHL28 mRNA
CTD
PMID:19074003
NCBI chr 6:86,680,826...86,713,370
Ensembl chr 6:86,684,413...86,713,370
G
Klhl4
kelch-like family member 4
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of KLHL4 mRNA testosterone undecanoate results in decreased expression of KLHL4 mRNA
CTD
PMID:19074003
NCBI chr X:86,125,929...86,229,565
Ensembl chr X:86,126,157...86,229,563
G
Klk13
kallikrein related-peptidase 13
increases expression
ISO
testosterone undecanoate results in increased expression of KLK13 mRNA
CTD
PMID:19074003
NCBI chr 1:99,648,658...99,661,025
Ensembl chr 1:99,648,658...99,660,277
G
Limd1
LIM domains containing 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of LIMD1 mRNA
CTD
PMID:19074003
NCBI chr 8:132,553,218...132,598,826
Ensembl chr 8:132,553,218...132,598,812
G
Lingo1
leucine rich repeat and Ig domain containing 1
increases expression
ISO
testosterone undecanoate results in increased expression of LINGO1 mRNA
CTD
PMID:19074003
NCBI chr 8:61,272,125...61,455,480
Ensembl chr 8:61,274,017...61,290,240
G
Lmntd1
lamin tail domain containing 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of LMNTD1 mRNA
CTD
PMID:19074003
NCBI chr 4:179,658,348...179,905,049
Ensembl chr 4:179,651,164...179,904,844
G
LOC681470
similar to olfactory receptor 1403
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of OR10J1 mRNA testosterone undecanoate results in increased expression of OR10J1 mRNA
CTD
PMID:19074003
NCBI chr13:91,768,256...91,769,188
Ensembl chr13:91,768,256...91,769,188
G
Lrig2
leucine-rich repeats and immunoglobulin-like domains 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of LRIG2 mRNA
CTD
PMID:19074003
NCBI chr 2:206,928,708...206,997,915
Ensembl chr 2:206,931,204...206,997,519
G
Man2a1
mannosidase, alpha, class 2A, member 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of MAN2A1 mRNA
CTD
PMID:19074003
NCBI chr 9:112,293,388...112,451,677
Ensembl chr 9:112,293,388...112,451,677
G
Mbnl1
muscleblind-like splicing regulator 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of MBNL1 mRNA
CTD
PMID:19074003
NCBI chr 2:150,698,248...150,867,791
Ensembl chr 2:150,756,185...150,869,690
G
Mep1b
meprin A subunit beta
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of MEP1B mRNA
CTD
PMID:19074003
NCBI chr18:15,063,159...15,090,877
Ensembl chr18:15,063,079...15,089,988
G
Midn
midnolin
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of MIDN mRNA
CTD
PMID:19074003
NCBI chr 7:12,414,303...12,426,712
Ensembl chr 7:12,414,733...12,424,367
G
Mro
maestro
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of MRO mRNA testosterone undecanoate results in decreased expression of MRO mRNA
CTD
PMID:19074003
NCBI chr18:69,833,770...69,850,164
G
Mrps6
mitochondrial ribosomal protein S6
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of MRPS6 mRNA
CTD
PMID:19074003
NCBI chr11:32,208,246...32,263,999
Ensembl chr11:32,211,115...32,263,899
G
Mtss1
MTSS I-BAR domain containing 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of MTSS1 mRNA
CTD
PMID:19074003
NCBI chr 7:98,820,799...98,960,878
Ensembl chr 7:98,820,812...98,960,837
G
Mysm1
myb-like, SWIRM and MPN domains 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of MYSM1 mRNA
CTD
PMID:19074003
NCBI chr 5:113,902,115...113,939,083
Ensembl chr 5:113,906,803...113,939,127
G
Nacc2
NACC family member 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of NACC2 mRNA
CTD
PMID:19074003
NCBI chr 3:3,508,084...3,574,787
Ensembl chr 3:3,510,041...3,574,787
G
Ndfip1
Nedd4 family interacting protein 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of NDFIP1 mRNA
CTD
PMID:19074003
NCBI chr18:31,574,759...31,625,286
Ensembl chr18:31,574,821...31,625,274
G
Nexn
nexilin (F actin binding protein)
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of NEXN mRNA
CTD
PMID:19074003
NCBI chr 2:257,452,937...257,484,607
Ensembl chr 2:257,453,347...257,484,587
G
Nid1
nidogen 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of NID1 mRNA
CTD
PMID:19074003
NCBI chr17:90,553,161...90,627,133
Ensembl chr17:90,553,394...90,627,101
G
Nsg1
neuronal vesicle trafficking associated 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of NSG1 mRNA
CTD
PMID:19074003
NCBI chr14:77,380,264...77,402,007
Ensembl chr14:77,380,262...77,401,996
G
Odf3
outer dense fiber of sperm tails 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of ODF3 mRNA
CTD
PMID:19074003
NCBI chr 1:213,596,784...213,602,417
Ensembl chr 1:213,597,478...213,600,685
G
Olfml3
olfactomedin-like 3
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of OLFML3 mRNA testosterone undecanoate results in decreased expression of OLFML3 mRNA
CTD
PMID:19074003
NCBI chr 2:206,219,419...206,222,248
Ensembl chr 2:206,219,419...206,222,248
G
Opn5
opsin 5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of OPN5 mRNA
CTD
PMID:19074003
NCBI chr 9:21,045,457...21,092,517
Ensembl chr 9:21,045,457...21,093,172
G
Osbpl10
oxysterol binding protein-like 10
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of OSBPL10 mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of OSBPL10 mRNA
CTD
PMID:19074003
NCBI chr 8:123,029,722...123,303,553
Ensembl chr 8:123,126,667...123,293,562
G
Pak3
p21 (RAC1) activated kinase 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PAK3 mRNA
CTD
PMID:19074003
NCBI chr X:114,784,452...115,042,683
Ensembl chr X:114,929,029...115,036,669
G
Pappa1
pappalysin 1
decreases expression multiple interactions
ISO
testosterone undecanoate results in decreased expression of PAPPA mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PAPPA mRNA
CTD
PMID:19074003
NCBI chr 5:80,919,932...81,153,904
Ensembl chr 5:80,920,568...81,150,940
G
Pard6b
par-6 family cell polarity regulator beta
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PARD6B mRNA
CTD
PMID:19074003
NCBI chr 3:164,822,111...164,843,395
Ensembl chr 3:164,822,111...164,843,395
G
Pcdh7
protocadherin 7
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PCDH7 mRNA
CTD
PMID:19074003
NCBI chr14:54,649,054...55,081,632
Ensembl chr14:55,072,200...55,081,551
G
Pde1c
phosphodiesterase 1C
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of PDE1C mRNA
CTD
PMID:19074003
NCBI chr 4:86,359,762...86,925,044
Ensembl chr 4:86,359,820...86,630,543
G
Pkp4
plakophilin 4
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PKP4 mRNA
CTD
PMID:19074003
NCBI chr 3:45,211,097...45,414,524
Ensembl chr 3:45,277,348...45,414,613
G
Plagl1
PLAG1 like zinc finger 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PLAGL1 mRNA
CTD
PMID:19074003
NCBI chr 1:7,219,587...7,270,169
Ensembl chr 1:7,252,349...7,259,035
G
Poglut1
protein O-glucosyltransferase 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of POGLUT1 mRNA
CTD
PMID:19074003
NCBI chr11:64,761,493...64,788,210
Ensembl chr11:64,761,146...64,788,208
G
Ppp2r2c
protein phosphatase 2, regulatory subunit B, gamma
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of PPP2R2C mRNA testosterone undecanoate results in increased expression of PPP2R2C mRNA
CTD
PMID:19074003
NCBI chr14:78,679,214...78,763,175
Ensembl chr14:78,679,214...78,902,063
G
Prkab1
protein kinase AMP-activated non-catalytic subunit beta 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of PRKAB1 mRNA
CTD
PMID:19074003
NCBI chr12:46,316,298...46,326,789
Ensembl chr12:46,316,236...46,326,790
G
Prkca
protein kinase C, alpha
increases expression
ISO
testosterone undecanoate results in increased expression of PRKCA mRNA
CTD
PMID:19074003
NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
G
Ptbp2
polypyrimidine tract binding protein 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PTBP2 mRNA
CTD
PMID:19074003
NCBI chr 2:223,261,444...223,323,075
Ensembl chr 2:223,262,852...223,322,585
G
Ptger2
prostaglandin E receptor 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PTGER2 mRNA
CTD
PMID:19074003
NCBI chr15:19,336,029...19,349,759
Ensembl chr15:19,338,175...19,350,210
G
Ptges
prostaglandin E synthase
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of PTGES mRNA testosterone undecanoate results in decreased expression of PTGES mRNA
CTD
PMID:19074003
NCBI chr 3:9,727,408...9,738,752
Ensembl chr 3:9,727,408...9,738,752
G
Rab11fip3
RAB11 family interacting protein 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of RAB11FIP3 mRNA
CTD
PMID:19074003
NCBI chr10:15,348,356...15,433,384
Ensembl chr10:15,349,888...15,381,691
G
Rab1a
RAB1A, member RAS oncogene family
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of RAB1A mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of RAB1A mRNA
CTD
PMID:19074003
NCBI chr14:104,475,082...104,500,176
Ensembl chr14:104,475,082...104,501,020
G
Rapgef6
Rap guanine nucleotide exchange factor 6
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of RAPGEF6 mRNA
CTD
PMID:19074003
NCBI chr10:39,875,322...40,039,929
Ensembl chr10:39,875,371...40,039,929
G
Recql
RecQ like helicase
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of RECQL mRNA
CTD
PMID:19074003
NCBI chr 4:176,581,892...176,606,520
Ensembl chr 4:176,581,897...176,606,382
G
Rftn2
raftlin family member 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of RFTN2 mRNA
CTD
PMID:19074003
NCBI chr 9:61,754,859...61,810,992
Ensembl chr 9:61,756,428...61,810,417
G
Rln1
relaxin 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of RLN1 mRNA
CTD
PMID:19074003
NCBI chr 1:247,483,298...247,486,331
Ensembl chr 1:247,483,302...247,486,202
G
Rnaseh1
ribonuclease H1
decreases expression
ISO
testosterone undecanoate results in decreased expression of RNASEH1 mRNA
CTD
PMID:19074003
NCBI chr 6:47,916,188...47,925,582
Ensembl chr 6:47,916,188...47,925,571
G
Rnf216
ring finger protein 216
increases expression multiple interactions
ISO
testosterone undecanoate results in increased expression of RNF216 mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of RNF216 mRNA
CTD
PMID:19074003
NCBI chr12:13,508,429...13,631,689
Ensembl chr12:13,508,429...13,632,304
G
Rnft1
ring finger protein, transmembrane 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of RNFT1 mRNA
CTD
PMID:19074003
NCBI chr10:73,807,455...73,821,178
Ensembl chr10:73,809,157...73,817,982
G
RT1-Bb
RT1 class II, locus Bb
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of HLA-DQB1 mRNA
CTD
PMID:19074003
NCBI chr20:4,043,726...4,049,367
Ensembl chr20:4,039,413...4,049,711
G
Rtn4
reticulon 4
decreases expression
ISO
testosterone undecanoate results in decreased expression of RTN4 mRNA
CTD
PMID:19074003
NCBI chr14:114,126,931...114,174,459
Ensembl chr14:114,126,943...114,174,458
G
Saraf
store-operated calcium entry-associated regulatory factor
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SARAF mRNA
CTD
PMID:19074003
NCBI chr16:61,735,189...61,753,438
Ensembl chr16:61,735,181...61,753,476
G
Scaf4
SR-related CTD-associated factor 4
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SCAF4 mRNA
CTD
PMID:19074003
NCBI chr11:30,371,713...30,428,073
Ensembl chr11:30,371,713...30,428,073
G
Senp1
SUMO specific peptidase 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SENP1 mRNA
CTD
PMID:19074003
NCBI chr 7:139,626,444...139,684,587
Ensembl chr 7:139,630,515...139,675,245
G
Serpinb3
serpin family B member 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SERPINB3 mRNA
CTD
PMID:19074003
NCBI chr13:27,186,701...27,193,211
Ensembl chr13:27,187,130...27,192,592
G
Sfrp5
secreted frizzled-related protein 5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SFRP5 mRNA
CTD
PMID:19074003
NCBI chr 1:261,442,108...261,446,570
Ensembl chr 1:261,442,108...261,446,570
G
Slc16a9
solute carrier family 16, member 9
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SLC16A9 mRNA testosterone undecanoate results in decreased expression of SLC16A9 mRNA
CTD
PMID:19074003
NCBI chr20:19,634,280...19,675,358
G
Slc25a2
solute carrier family 25 member 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SLC25A2 mRNA
CTD
PMID:19074003
NCBI chr18:30,774,205...30,775,401
Ensembl chr18:30,774,205...30,775,401
G
Slc2a5
solute carrier family 2 member 5
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SLC2A5 mRNA
CTD
PMID:19074003
NCBI chr 5:167,142,182...167,174,203
Ensembl chr 5:167,141,875...167,174,310
G
Slc6a5
solute carrier family 6 member 5
increases expression
ISO
testosterone undecanoate results in increased expression of SLC6A5 mRNA
CTD
PMID:19074003
NCBI chr 1:105,270,418...105,336,369
Ensembl chr 1:105,284,753...105,336,363
G
Smyd2
SET and MYND domain containing 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SMYD2 mRNA
CTD
PMID:19074003
NCBI chr13:108,642,156...108,686,293
Ensembl chr13:108,642,156...108,686,290
G
Snrpn
small nuclear ribonucleoprotein polypeptide N
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SNRPN mRNA
CTD
PMID:19074003
NCBI chr 1:195,074,328...195,096,460
Ensembl chr 1:195,074,330...195,096,460
G
Sobp
sine oculis binding protein homolog
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of SOBP mRNA
CTD
PMID:19074003
NCBI chr20:47,731,713...47,910,466
Ensembl chr20:47,750,762...47,910,375
G
Spin4
spindlin family, member 4
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SPIN4 mRNA
CTD
PMID:19074003
NCBI chr X:64,217,074...64,221,225
G
Sptbn1
spectrin, beta, non-erythrocytic 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SPTBN1 mRNA
CTD
PMID:19074003
NCBI chr14:114,517,839...114,700,199
Ensembl chr14:114,518,816...114,692,764
G
Srgn
serglycin
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SRGN mRNA testosterone undecanoate results in decreased expression of SRGN mRNA
CTD
PMID:19074003
NCBI chr20:32,120,317...32,158,071
Ensembl chr20:32,120,320...32,139,789
G
Srp68
signal recognition particle 68
increases expression
ISO
testosterone undecanoate results in increased expression of SRP68 mRNA
CTD
PMID:19074003
NCBI chr10:105,123,324...105,150,080
Ensembl chr10:105,123,327...105,228,547
G
Stxbp5l
syntaxin binding protein 5-like
multiple interactions increases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of STXBP5L mRNA testosterone undecanoate results in increased expression of STXBP5L mRNA
CTD
PMID:19074003
NCBI chr11:66,246,624...66,566,331
Ensembl chr11:66,316,606...66,566,331
G
Syt11
synaptotagmin 11
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of SYT11 mRNA
CTD
PMID:19074003
NCBI chr 2:188,112,301...188,138,180
Ensembl chr 2:188,112,286...188,138,177
G
Tfdp2
transcription factor Dp-2
decreases expression
ISO
testosterone undecanoate results in decreased expression of TFDP2 mRNA
CTD
PMID:19074003
NCBI chr 8:104,040,795...104,181,228
Ensembl chr 8:104,040,934...104,176,446
G
Thpo
thrombopoietin
increases expression
ISO
testosterone undecanoate results in increased expression of THPO mRNA
CTD
PMID:19074003
NCBI chr11:82,845,676...82,853,439
Ensembl chr11:83,868,655...83,873,910 Ensembl chr11:83,868,655...83,873,910
G
Tmem217
transmembrane protein 217
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of TMEM217 mRNA
CTD
PMID:19074003
NCBI chr20:8,202,165...8,202,956
Ensembl chr20:8,202,355...8,202,924
G
Tmem225
transmembrane protein 225
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of TMEM225 mRNA
CTD
PMID:19074003
NCBI chr 8:44,001,199...44,003,757
Ensembl chr 8:44,001,096...44,004,044
G
Tmem35a
transmembrane protein 35A
multiple interactions decreases expression
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of TMEM35A mRNA testosterone undecanoate results in decreased expression of TMEM35A mRNA
CTD
PMID:19074003
NCBI chr X:105,134,498...105,145,346
Ensembl chr X:105,134,498...105,145,345
G
Tmod2
tropomodulin 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of TMOD2 mRNA
CTD
PMID:19074003
NCBI chr 8:82,505,947...82,547,450
Ensembl chr 8:82,506,934...82,533,689
G
Tnrc6b
trinucleotide repeat containing adaptor 6B
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of TNRC6B mRNA
CTD
PMID:19074003
NCBI chr 7:121,930,610...122,147,934
Ensembl chr 7:121,930,615...122,147,934
G
Tra2a
transformer 2 alpha homolog
decreases expression multiple interactions
ISO
testosterone undecanoate results in decreased expression of TRA2A mRNA [testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of TRA2A mRNA
CTD
PMID:19074003
NCBI chr 4:78,905,380...78,924,203
Ensembl chr 4:78,905,380...78,924,181
G
Trmt13
tRNA methyltransferase 13 homolog
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of TRMT13 mRNA
CTD
PMID:19074003
NCBI chr 2:219,615,665...219,628,824
Ensembl chr 2:219,615,420...219,628,997
G
Ttc37
tetratricopeptide repeat domain 37
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of TTC37 mRNA
CTD
PMID:19074003
NCBI chr 2:2,891,265...3,037,602
Ensembl chr 2:2,903,492...3,004,553
G
Tubb2a
tubulin, beta 2A class IIa
increases expression
ISO
testosterone undecanoate results in increased expression of TUBB2A mRNA
CTD
PMID:19074003
NCBI chr17:31,493,145...31,496,827
Ensembl chr17:31,493,107...31,498,651
G
Ubap1
ubiquitin-associated protein 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of UBAP1 mRNA
CTD
PMID:19074003
NCBI chr 5:57,738,309...57,778,724
Ensembl chr 5:57,738,321...57,778,723
G
Ube2d3
ubiquitin-conjugating enzyme E2D 3
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of UBE2D3 mRNA
CTD
PMID:19074003
NCBI chr 2:240,626,198...240,655,874
Ensembl chr 2:240,627,436...240,655,246
G
Unc13c
unc-13 homolog C
increases expression
ISO
testosterone undecanoate results in increased expression of UNC13C mRNA
CTD
PMID:19074003
NCBI chr 8:80,202,736...80,656,363
Ensembl chr 8:80,203,609...80,631,926
G
Xiap
X-linked inhibitor of apoptosis
decreases expression
ISO
testosterone undecanoate results in decreased expression of XIAP mRNA
CTD
PMID:19074003
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
G
Xylt1
xylosyltransferase 1
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of XYLT1 mRNA
CTD
PMID:19074003
NCBI chr 1:186,939,698...187,264,758
Ensembl chr 1:187,149,453...187,261,632
G
Yeats2
YEATS domain containing 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of YEATS2 mRNA
CTD
PMID:19074003
NCBI chr11:84,330,064...84,595,296
Ensembl chr11:84,330,064...84,583,542
G
Zcchc7
zinc finger CCHC-type containing 7
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ZCCHC7 mRNA
CTD
PMID:19074003
NCBI chr 5:60,250,546...60,430,119
Ensembl chr 5:60,250,546...60,429,708
G
Zeb2
zinc finger E-box binding homeobox 2
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ZEB2 mRNA
CTD
PMID:19074003
NCBI chr 3:29,857,289...29,985,932
Ensembl chr 3:29,862,473...29,996,865
G
Zfand6
zinc finger AN1-type containing 6
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ZFAND6 mRNA
CTD
PMID:19074003
NCBI chr 1:146,745,850...146,823,762
Ensembl chr 1:146,745,859...146,823,762
G
Zfp518a
zinc finger protein 518A
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ZNF518A mRNA
CTD
PMID:19074003
NCBI chr 1:260,152,881...260,178,360
Ensembl chr 1:260,153,645...260,178,349
G
Zfp638
zinc finger protein 638
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ZNF638 mRNA
CTD
PMID:19074003
NCBI chr 4:115,555,185...115,690,272
Ensembl chr 4:115,601,661...115,690,272
G
Zfr
zinc finger RNA binding protein
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in decreased expression of ZFR mRNA
CTD
PMID:19074003
NCBI chr 2:62,150,251...62,213,048
Ensembl chr 2:62,150,251...62,213,048
G
Zkscan7
zinc finger with KRAB and SCAN domains 7
multiple interactions
ISO
[testosterone undecanoate co-treated with Levonorgestrel] results in increased expression of ZKSCAN7 mRNA
CTD
PMID:19074003
NCBI chr 8:131,932,753...131,968,550
Ensembl chr 8:131,933,387...131,950,776
Term paths to the root one shortest all shortest one longest all longest one shortest and longest all